title: Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens.
abstract: In this study we surveyed the average survival time of the treated Hodgkin's lymphoma patients and also the side effects and malignancies occurring secondary to the treatment. This is a retrospective study of patients referring to Ahwaz's Shafa hospital in a period of 10 years diagnosed with Hodgkin's lymphoma without any age restriction. After gathering all their data, we calculated their survival rate and the chance for a relapse and the secondary malignancies. 389 patients were included in the study with an average age of 27.5 years old and they had received only chemotherapy regimens. 87.9% of them had been treated by ABVD and 12.1 % by Stanford V regimen. 23.1% of them experienced a relapse and 13.1% of all patients, passed away during the study. Secondary malignancies were observed in 11 cases. An overall mean survival time of 295.31 months was resulted. The secondary malignancies after treating Hodgkin's lymphoma patients are different between chemotherapy regimens and chemotherapy - radiotherapy.
authors.affiliation: Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Ahmadzadeh
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mir Saeed
authors.initials: MS
authors.lastname: Yekaninejad
authors.affiliation: Department of internal medicine, school of medicine, Tehran University of medical sciences, Tehran, Iran.
authors.forename: Mohamad H
authors.initials: MH
authors.lastname: Jalili
authors.affiliation: Department of internal medicine, school of medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Bahadoram
authors.affiliation: Department of internal medicine, school of medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Efazat
authors.affiliation: Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Seghatoleslami
authors.affiliation: Department of internal medicine, Ganjavian hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Yazdi
authors.affiliation: Department of surgery, Arvand hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.
authors.forename: Mozhdeh
authors.initials: M
authors.lastname: Mahdipour
authors.affiliation: Department of Anatomy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors.forename: Armita
authors.initials: A
authors.lastname: Valizadeh
authors.affiliation: Health research institute, Research Center of Thalassemia & Hemoglobinopathy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors.forename: Najmaldin
authors.initials: N
authors.lastname: Saki
keywords: Chemotherapy; Hodgkin; Second malignancy; Survival